Maze Therapeutics (NASDAQ:MAZE) CMO Sells $134,965.89 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 5,189 shares of the firm’s stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $26.01, for a total value of $134,965.89. Following the completion of the sale, the chief marketing officer owned 9,705 shares of the company’s stock, valued at approximately $252,427.05. This represents a 34.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Harold Bernstein also recently made the following trade(s):

• On Wednesday, September 2nd, Harold Bernstein sold 5,106 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.47, for a total value of $135,155.82.
• On Tuesday, September 1st, Harold Bernstein sold 16,141 shares of Maze Therapeutics stock. The stock was sold at an average price of $26.36, for a total value of $425,476.76.
• On Thursday, August 13th, Harold Bernstein sold 16,142 shares of Maze Therapeutics stock. The stock was sold at an average price of $27.61, for a total value of $445,680.62.
• On Wednesday, July 1st, Harold Bernstein sold 14,609 shares of Maze Therapeutics stock. The shares were sold at an average price of $29.90, for a total value of $436,809.10.

Maze Therapeutics Stock Up 1.3%

Shares of NASDAQ:MAZE traded up $0.34 during trading on Friday, reaching $26.21. 273,266 shares of the stock were exchanged, compared to its average volume of 637,671. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31. Maze Therapeutics, Inc. has a 1-year low of $14.27 and a 1-year high of $53.65. The stock has a fifty day moving average of $28.74 and a two-hundred day moving average of $31.20. The firm has a market cap of $1.46 billion, a price-to-earnings ratio of -10.40 and a beta of 2.17.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.76). Research analysts anticipate that Maze Therapeutics, Inc. will post -2.72 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. TD Cowen raised shares of Maze Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. Wall Street Zen downgraded Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, BTIG Research reiterated a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a research note on Wednesday, August 12th. Three analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Maze Therapeutics presently has a consensus rating of “Buy” and an average price target of $66.00.

Hedge Funds Weigh In On Maze Therapeutics

Several large investors have recently bought and sold shares of the stock. ARCH Venture Management LLC bought a new stake in Maze Therapeutics during the second quarter worth $122,983,582. Alphabet Inc. bought a new position in Maze Therapeutics in the 2nd quarter valued at $41,435,000. TRV GP IV LLC bought a new position in Maze Therapeutics in the 2nd quarter valued at $133,502,907. Spruce Street Capital LP purchased a new stake in shares of Maze Therapeutics during the 1st quarter valued at $5,970,000. Finally, Boothbay Fund Management LLC raised its stake in shares of Maze Therapeutics by 16.3% during the 4th quarter. Boothbay Fund Management LLC now owns 409,372 shares of the company’s stock worth $16,960,000 after purchasing an additional 57,497 shares during the period.

Trending Headlines about Maze Therapeutics

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Analyst sentiment remains broadly constructive. TD Cowen upgraded MAZE to “strong buy,” BTIG reiterated a “buy” rating with a $46 price target, and the consensus rating is “buy” with an average target of $66.00. Maze Therapeutics insider trading and analyst coverage
• Neutral Sentiment: Institutional ownership activity included purchases or position increases by Royal Bank of Canada, Russell Investments Group and other firms. These holdings are relatively small, however, and are unlikely to be a major near-term price driver.
• Neutral Sentiment: Maze’s CEO Jason Coloma, CMO Harold Bernstein and other insiders sold shares between September 1 and September 3. Combined reported sales totaled roughly $2.4 million, but the filings said the transactions were made to cover tax obligations from equity vesting; Bernstein’s September 1 sale was also conducted under a pre-arranged Rule 10b5-1 plan. SEC insider trading filing
• Negative Sentiment: The scale and repetition of insider selling may weigh on investor sentiment, particularly as the CEO reduced his directly held shares substantially. MAZE has also been trading below its 50-day and 200-day moving averages, signaling continued technical weakness. The company remains loss-making, with quarterly EPS of negative $0.76 and analysts expecting approximately negative $2.72 EPS for the year.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical?stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de?risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.